Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company
leveraging novel next-generation sequencing (NGS) and spatial
multiomics technologies to empower researchers and clinicians,
today unveiled the G4X™ Spatial Sequencer. The G4X is designed to
offer high-throughput in situ direct sequencing of RNA
(Direct-Seq™), targeted transcriptomics, and proteomics profiling
from formalin-fixed, paraffin-embedded (FFPE) tissues. The G4X will
share the same platform as the existing G4® sequencer and is
expected to be the industry’s first dual-purpose instrument
offering both traditional NGS and tissue-based spatial sequencing
capabilities. With the addition of high-throughput multiomics and
novel Direct-Seq technology to its portfolio with the G4X, Singular
is positioned to become the only company worldwide to offer in situ
spatial sequencing of tissues and NGS on the same instrument.
The G4X Spatial Sequencer is designed to offer novel
capabilities, stackable data streams, and unprecedented throughput
for spatial profiling of tissue. Its novel capabilities will
include Direct-Seq, which is the sequencing of RNA molecules in
situ and has the potential to open new areas of scientific
discovery. In addition, the G4X will offer readouts of targeted
transcripts, targeted proteins, and a fluorescent H&E stain,
all in the same tissue sample. And lastly, this combination of
readout modalities will be offered at an unprecedented scale. With
40 cm2 of flexible imaging area and single-day run times, the G4X
system will enable labs to process 20 times more samples per week
than existing technologies.
“We founded Singular with a commitment to listen to our
customers, to innovate, and to bring products to market that have
an impact,” stated Drew Spaventa, co-founder and Chief Executive
Officer of Singular Genomics. “The G4X embodies this commitment by
providing new capabilities, novel data streams, and scale. This
powerful combination has the potential to open new areas of
discovery, accelerate research, and advance the medical field.”
Initial kits on the G4X will support transcription, proteomics,
and offer a fluorescent H&E stain. The system is designed to
accommodate a large number of samples and will read out hundreds of
gene targets and dozens of proteins in the same tissue section.
Content will be available in fixed panels or customizable for the
customer. Future kits on the G4X will also support Direct-Seq,
which is designed to directly read variable regions of RNA, such as
cancer hotspot mutations, guide RNAs in CRISPR screens, or B- and
T-cell receptor sequences. The capability to perform direct
sequencing of RNA within cells and tissues is expected to bring a
powerful new readout modality for in situ molecular pathology.
Direct-Seq will be initially available as a service, with plans for
broader release shortly thereafter.
“Building on our foundation in NGS, we saw an opportunity to
bring sequencing directly into cells and tissues, and to create a
universal readout for spatial biology,” said Eli Glezer, co-founder
and Chief Scientific Officer of Singular Genomics. “Our spatial
sequencing technology will enable in situ detection of gene
transcripts, multiplexed imaging of proteins, and direct reading of
mutations or variable gene regions, all in the same tissue sample.
With its unprecedented throughput and direct spatial sequencing, we
believe the G4X will usher in a new era of in situ multiomic
analysis.”
“As the first location to have the G4 worldwide, we are thrilled
about the spatial capabilities that can be added to our existing
instrument, since it will allow us to perform both NGS and spatial
tissue profiling on the same platform” said Ioannis Vlachos,
Associate Professor, Harvard Medical School, and Director of
Spatial Technologies, HMS Initiative for RNA Medicine, Department
of Pathology, Beth Israel Deaconess Medical Center. “As the spatial
biology field matures, high throughput spatial platforms, such as
the G4X, will empower more researchers to incorporate spatial
tissue profiling into their work as well as enable us to answer
bigger questions and to perform increasingly larger studies.”
Singular previously announced a technology access program for
the PX, the learnings from which have been applied to the
development of the G4X. Through its technology access program,
Singular has been actively collaborating with leading institutions
to generate data on the G4X and demonstrate its applicability in
critical research areas.
“The high sample throughput and the excellent data quality that
has been generated on the G4X with our bone marrow
samples—notoriously a very difficult tissue type—have been
impressive and have allowed us to envision much larger studies that
have not been previously possible,” said Catherine Wu, Chief,
Stem Cell Transplantation & Cellular Therapies, Harvard Medical
School. “The scale provided by the G4X promises to have a
tremendous impact on expanding our understanding of the tumor
microenvironment in acute myelogenous leukemia (AML) and
beyond.”
Expected Key Features of the G4X™ Spatial
Sequencer:
- Industry-leading Throughput: An imaging area
of 40 cm2 per run across four spatial flow cells is expected to
dramatically increase sample throughput while retaining flexibility
for smaller runs.
- Direct-Seq: In situ sequencing of RNA,
designed to sequence variable gene regions directly within cells
and tissues, with potential applications in immunology,
immuno-oncology, cancer research, and gene editing.
- Transcripts: Hundreds of gene transcripts,
which will be available in curated panels and custom gene target
selection.
- Proteins: Dozens of proteins, which will be
available in curated panels and custom protein target
selection.
- Fluorescent H&E: Fluorescent H&E stain
overlayed with transcripts and proteins on the same tissue
sample.
- Rapid Turn-around-time: With a specialized
tissue transfer process, streamlined sample preparation workflow,
and high-speed single-day sequencing, users will have the ability
to go from sample-to-discovery in just three days.
- Cost-Effective: With its unprecedented
throughput, the G4X will significantly reduce the cost per sample
to less than half that of alternative approaches, making spatial
multiomics more accessible.
The system is listed at $495,000, G4X upgrades are expected to
be available to G4 customers by the end of 2024, along with an
initial immuno-oncology panel of approximately 300 gene
transcripts, 10-15 proteins, and the ability to customize content.
Direct-Seq and additional panels are expected to be released at a
later date. Singular also plans to provide G4X Spatial Sequencing
Technology Access Services starting in the second quarter of 2024.
The company plans to share more information and data at the
upcoming annual AGBT General Meeting in Orlando, Florida (February
5–8, 2024).
Learn more about the G4X Spatial Sequencer at
www.singulargenomics.com/g4x.
About Singular Genomics Systems, Inc.
Singular Genomics is a life science technology company that
develops next-generation sequencing and multiomics technologies.
The commercially available G4® Sequencing Platform is a powerful,
highly versatile benchtop genomic sequencer designed to produce
fast and accurate results. In addition, the company is currently
developing the G4X™ Spatial Sequencer, an upgrade to the G4, which
will leverage Singular’s proprietary sequencing technology,
applying it as an in situ readout for transcriptomics, proteomics
and fluorescent H&E in tissue, with spatial context. Singular
Genomics’ mission is to empower researchers and clinicians to
advance science and medicine. Visit www.singulargenomics.com
for more information.
Forward Looking Statements
Certain statements contained in this press release, other than
historical information, constitute forward-looking statements
within the meaning of the federal securities laws. Forward-looking
statements include, but are not limited to, statements regarding:
(i) our timeline and successful development of the G4X and the
ability to deliver associated services; (ii) expected features,
capabilities and specifications of the G4X and the ability to
deliver associated services; (iii) our ability to successfully
manufacture, commercialize and support the G4, G4X and our flow
cell kits in accordance with our timelines, objectives and
specifications; and (iv) quotes of management. Any such
forward-looking statements are based on our management’s current
expectations and are subject to risks and uncertainties that could
cause our actual future results to differ materially from our
management’s current expectations or those implied by our
forward-looking statements. These risks and uncertainties include,
but are not limited to, the following: (i) we are currently
developing the G4X Spatial Sequencer and may not be successful in
completing its development on our projected timeline, with the
features and capabilities we expect, or at the cost we anticipate;
(ii) we have very little history manufacturing and commercializing
our products or technology; (iii) the life sciences technology
market is highly competitive, and if we fail to compete
effectively, our business and operating results will suffer; (iv)
if we are sued for infringing, misappropriating or otherwise
violating intellectual property rights of third parties, such
litigation could be costly and time consuming and could prevent or
delay us from developing or commercializing our products; (v) if
our products fail to achieve early customer and scientific
acceptance, we may not be able to achieve broader market acceptance
for our products, and our revenues and prospects may be harmed;
(vi) we expect to be highly dependent upon revenue generated from
the sale of the G4 and future products, and any delay or failure by
us to successfully manufacture and commercialize the G4 and future
products could have a substantial adverse effect on our business
and results of operations; and (vii) recent macroeconomic
challenges such as inflation and rising interest rates may
materially and adversely impact our business, operations, product
manufacturing and commercialization objectives. These and other
risk factors that may affect our future results of operations are
identified and described in more detail in our most recent filings
on Forms 10-K and 10-Q and in other filings that we make with the
SEC from time to time, including our Quarterly Report on Form 10-Q
for the period ended September 30, 2023, filed with the SEC on
November 14, 2023. Accordingly, you should not rely on
forward-looking statements as predictions of future events or our
future performance. Except as required by law, we undertake no
obligation to update publicly or revise any forward-looking
statements contained herein, whether as a result of any new
information, future events, changed circumstances or otherwise.
Investor Contact
Matt Clawson949-370-8500ir@singulargenomics.com
Media Contact
Dan Budwick, 1AB973-271-6085dan@1abmedia.com
Singular Genomics Systems (NASDAQ:OMIC)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Singular Genomics Systems (NASDAQ:OMIC)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024